EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modified Citrus Pectin-Mediated Gal-3 Reduction Attenuates Metabolic Dysfunction-Associated Steatohepatitis in an Experimental Model

Anne R M Santos iD, Alessandra G Cruz iD, Felipe N Camargo iD, Jessica D M Santos iD, Jorge F A Model iD, José F T Silva, Sandro L Matos iD, Layanne C C Araujo iD, João Paulo Camporez iD

Cells · 2026

DOI: 10.3390/cells15171544 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Anne R M Santos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto 14049-900, Brazil. Hauptthemen laut MEDLINE: Pectins, Galectin 3, Fatty Liver. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Coordenação de Aperfeicoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by hepatic steatosis, inflammation, fibrosis, and metabolic dysfunction, with limited therapeutic options currently available. This study investigated whether pharmacological inhibition of Galectin-3 (Gal-3), a β-galactoside-binding lectin implicated in inflammation and fibrosis, using modified citrus pectin (MCP), attenuates established MASH in ApoE-deficient mice. Mice were assigned to four groups: standard chow (CTL), standard chow plus MCP (CTL + MCP), Western diet with fructose-enriched drinking water (WD), and WD plus MCP (WD + MCP). MCP (1% in drinking water) was administered during the final four weeks of the 11-week experimental protocol, after the establishment of metabolic dysfunction and hepatic steatosis. Compared with untreated WD mice, WD + MCP mice exhibited improved glucose tolerance, as evidenced by a 22.9% reduction in glucose area under the curve (p = 0.01), and enhanced hepatic insulin signaling, reflected by a 254.1% increase in insulin-stimulated AKT2 phosphorylation (p = 0.0002). MCP treatment also reduced hepatic lipid accumulation (39.8%, p = 0.0055) and hepatic triglyceride content (26.1%, p = 0.0003), accompanied by reductions in circulating triglyceride and cholesterol concentrations. Furthermore, WD + MCP mice exhibited reduced hepatic Gal-3 expression (25.8%, p = 0.0199), decreased F4/80 immunoreactivity (49.2%, p = 0.0061), attenuated JNK phosphorylation (46.6%, p = 0.0118), reduced collagen deposition (47.0%, p = 0.0002), and lower plasma ALT (52.9%, p = 0.0009) and AST (48.8%, p = 0.04) activities. Collectively, these findings demonstrate that MCP attenuates multiple metabolic, inflammatory, fibrotic, and hepatic injury features of established Western diet-induced MASH, supporting Gal-3 as a promising therapeutic target and MCP as a potential pharmacological strategy for MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PectinsGalectin 3Fatty LiverAnimalsMiceDisease Models, AnimalMaleLiverMice, Inbred C57BLSignal Transduction

Stichwörter der Autor:innen

Galectin-3hepatic insulin resistancehepatic steatosisinflammationliver fibrosismetabolic dysfunction-associated steatohepatitismodified citrus pectin

Substanzen

Pectinscitrus pectinGalectin 3

Autor:innen und Institutionen

  • Department of Physiology, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto 14049-900, Brazil.
  • Superior Institute of Biomedical Sciences, Faculty of Education and Integrated Sciences, State University of Ceara, Fortaleza 60714-903, Brazil.

ORCID-Profile: Anne R M Santos, Alessandra G Cruz, Felipe N Camargo, Jessica D M Santos, Jorge F A Model, Sandro L Matos, Layanne C C Araujo, João Paulo Camporez

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Coordenação de Aperfeicoamento de Pessoal de Nível Superior
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • FAPESP
  • CNPq
  • CAPES

Zitieren

APA

Santos, A. R. M., Cruz, A. G., Camargo, F. N., Santos, J. D. M., Model, J. F. A., Silva, J. F. T., Matos, S. L., Araujo, L. C. C., & Camporez, J. P. (2026). Modified Citrus Pectin-Mediated Gal-3 Reduction Attenuates Metabolic Dysfunction-Associated Steatohepatitis in an Experimental Model. Cells. https://doi.org/10.3390/cells15171544

Vancouver

Santos ARM, Cruz AG, Camargo FN, Santos JDM, Model JFA, Silva JFT, et al. Modified Citrus Pectin-Mediated Gal-3 Reduction Attenuates Metabolic Dysfunction-Associated Steatohepatitis in an Experimental Model. Cells. 2026. doi:10.3390/cells15171544

BibTeX
@article{Santos2026,
  author = {Santos, Anne R M and Cruz, Alessandra G and Camargo, Felipe N and Santos, Jessica D M and Model, Jorge F A and Silva, José F T and Matos, Sandro L and Araujo, Layanne C C and Camporez, João Paulo},
  title = {Modified Citrus Pectin-Mediated Gal-3 Reduction Attenuates Metabolic Dysfunction-Associated Steatohepatitis in an Experimental Model},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15171544}
}
Kostenlos starten →